Northern Trust Corp Janux Therapeutics, Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 201,983 shares of JANX stock, worth $8.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

201,983

Previous 204,002 0.99%

Holding current value

$8.46 Million

Previous $2.19 Million 247.53%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$7.93 - $49.75 $16,010 - $100,445	-2,019 Reduced 0.99%	201,983 $7.6 Million
Q4 2023 Feb 13, 2024	BUY	$5.85 - $11.7 $66,204 - $132,408	11,317 Added 5.87%	204,002 $2.19 Million
Q3 2023 Nov 13, 2023	BUY	$9.56 - $14.0 $51,576 - $75,530	5,395 Added 2.88%	192,685 $1.94 Million
Q2 2023 Aug 11, 2023	BUY	$11.08 - $15.92 $524,294 - $753,318	47,319 Added 33.81%	187,290 $2.22 Million
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $2,733 - $5,397	243 Added 0.17%	139,971 $1.69 Million

Q4 2022 Feb 13, 2023	BUY	$11.1 - $18.26 $37,340 - $61,426	3,364 Added 2.47%	139,728 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $34,699 - $54,005	3,207 Added 2.41%	136,364 $1.85 Million
Q2 2022 Aug 12, 2022	SELL	$9.52 - $15.65 $67,496 - $110,958	-7,090 Reduced 5.06%	133,157 $1.63 Million
Q1 2022 May 13, 2022	BUY	$13.24 - $20.24 $327,716 - $500,980	24,752 Added 21.43%	140,247 $2.01 Million
Q4 2021 Feb 08, 2022	SELL	$15.44 - $27.32 $22,635 - $40,051	-1,466 Reduced 1.25%	115,495 $2.28 Million
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $2.42 Million - $4.06 Million	116,961 New	116,961 $2.53 Million

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Janux Therapeutics, Inc. Transaction History